Close Menu

University of Oxford

Data to Look Over

According to the Los Angeles Times, National Institutes of Health officials are concerned about the possible side effect reported by a COVID-19 vaccine trial.

In PNAS this week: modeling of Rift Valley Fever spillover, Asian mosquito could pose malaria threat, and more.

Back Up in the UK

After a pause, AstraZeneca has resumed its COVID-19 vaccine clinical trial in the UK, according to NPR.

UK-based ATDBio will develop new oligonucleotide-tagged microbeads for use in droplet-based single-cell RNA sequencing, to be evaluated by researchers at Oxford.

According to Reuters, AstraZeneca has begun enrolling participants into a late-stage study of its candidate SARS-CoV-2 vaccine.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.

The New York Times reports two additional investigational vaccines appear to generate an immune response against SARS-CoV-2.

The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease. 

In Science this week: Fiber-seq method to examine regulatory architecture, mutations in SOST associated with osteoporosis drug-linked cardiovascular events, and more.


The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts. 




Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.